FrancophonIA/ELRC3.0 huggingface dataset:
English: Pelzont is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly ‘combined mixed dyslipidaemia' and ‘primary hypercholesterolaemia'.
Estonian: Pelzonti kasutatakse düslipideemiaga (vere ebaharilikult suure rasvasisaldusega) patsientide ravis lisaks dieedile ja füüsilisele koormusele, eelkõige kombineeritud segatüüpi düslipideemia ja primaarse hüperkolesteroleemia korral.
English: Primary hypercholesterolaemia is when the levels of cholesterol in the blood are high.
Estonian: Primaarse hüperkolesteroleemia korral on vere kolesteroolisisaldus suurenenud.
English: The effects of Pelzont were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Pelzonti toimet muude katsetega.
English: The first study compared the effectiveness of Pelzont with that of nicotinic acid alone or placebo (a dummy treatment) in reducing the levels of LDL cholesterol in a total of 1,613 patients.
Estonian: Esimeses uuringus võrreldi Pelzonti efektiivsust LDL-kolesterooli sisalduse vähendamisel üksnes nikotiinhappe või platseebo (näiva ravimi) efektiivsusega kokku 1613 patsiendil.
English: What benefit has Pelzont shown during the studies?
Estonian: Milles seisneb uuringute põhjal Pelzonti kasulikkus?
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Pelzont's benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.
Estonian: Inimravimite komitee jõudis otsusele, et Pelzonti kasulikkus düslipideemia ravis (eelkõige kombineeritud segatüüpi düslipideemia ja primaarse hüperkolesteroleemia ravis) on suurem kui sellega kaasnevad riskid.
English: In the first and third studies, fewer patients taking Pelzont reported moderate, severe or extreme flushing than patients taking nicotinic acid alone.
Estonian: Esimeses ja kolmandas uuringus täheldati tugevat või ülitugevat nahapunetust vähem nende patsientide hulgas, kes said Pelzonti, , võrreldes patsientidega, kes said ainult nikotiinhapet.
English: What is Pelzont used for?
Estonian: Milleks Pelzonti kasutatakse?
English: Flushing was measured using the flushing symptom questionnaire.
Estonian: Nahapunetuse mõõtmisel kasutati nahapunetuse küsimustikke.
English: How does Pelzont work?
Estonian: Kuidas Pelzont toimib?
English: How is Pelzont used?
Estonian: Kuidas Pelzonti kasutatakse?
English: Other information about Pelzont:
Estonian: Muu teave Pelzonti kohta
English: How has Pelzont been studied?
Estonian: Kuidas Pelzonti uuriti?
English: and what is it used for?
Estonian: ja milleks seda kasutatakse?
English: darunavir
Estonian: darunaviir
English: be approved for use in the EU.
Estonian: kasutamise Euroopa Liidus heaks kiita.
English: can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This allows effective treatment while avoiding a higher dose of darunavir.
Estonian: See võimaldab efektiivset ravi, vältides samal ajal darunaviiri suuremat annust.
English: does not cure HIV infection or AIDS, but HIV treatment may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: ei ravi HIV-nakkust ega AIDSi välja, kuid HIV-ravi võib edasi lükata immuunsüsteemi kahjustumist ja AIDSiga seotud nakkuste ja haiguste teket.
English: Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Estonian: Kaks ravimit on bioekvivalentsed, kui mõlemad tekitavad organismis sama toimeainesisalduse ning seega eeldatavalt omavad sama toimet.
English: may be given to adults or children from 3 years of age and weighing at least 15 kg.
Estonian: tohib manustada täiskasvanutele või vähemalt 15 kg kehamassiga vähemalt 3-aastastele lastele.
English: is a ‘generic medicine'.
Estonian: on geneeriline ravim.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Darunavir Krka d.d.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Darunavir Krka d.d.
English: approved?
Estonian: heaks kiideti?
English: When the enzyme is blocked, the virus does not reproduce normally, slowing down its multiplication in the body.
Estonian: Kui ensüüm on blokeeritud, on viiruse normaalne paljunemine häiritud ning selle levik organismis aeglustub.
English: contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Prezista.
Estonian: sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Prezista, millel juba on Euroopa Liidus müügiluba.
English: It blocks protease, an enzyme involved in the reproduction of HIV.
Estonian: See blokeerib HIV-nakkuse paljunemisel osaleva ensüümi proteaasi.
English: The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Estonian: Ettevõte tegi ka uuringud, mis tõendasid ravimi bioekvivalentsust võrdlusravimiga.
English: is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: on viirusravim, mida kasutatakse koos teiste HIV-vastaste ravimitega omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese 1. tüüpi immuunpuudulikkuse viirusega (HIV-1) patsientide raviks.
English: For more information on generic medicines, see the questionand-answer document here.
Estonian: Lisateave geneeriliste ravimite kohta on teabedokumendis siin.
English: Ritonavir reduces the breakdown of darunavir, increasing the levels of darunavir in the blood.
Estonian: Ritonaviir vähendab darunaviiri lagunemist, suurendades darunaviiri sisaldust veres.
English: For more information about treatment with Darunavir Krka d.d., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Darunavir Krka d.d.-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The medicine is to be taken with low-dose ritonavir or, as an alternative in adults, with cobicistat and with other HIV medicines, and should be taken with food.
Estonian: Ravimit kasutatakse koos väikeses annuses ritonaviiriga või täiskasvanutel koos kobitsistaadiga ja teiste HIV-ravimitega ning seda tuleb võtta koos toiduga.
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Prezista, and do not need to be repeated for Darunavir Krka d.d.
Estonian: Võrdlusravimiga Prezista on juba tehtud toimeaine heakskiidetud kasutusviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Darunavir Krka d.d.
English: is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: is always given with ritonavir.
Estonian: Darunavir Krka d.d.-d manustatakse alati koos ritonaviiriga.
English: can only be obtained with a prescription and treatment should be started by a healthcare professional who has experience in the management of HIV.
Estonian: on retseptiravim ja ravi peab alustama HIV ravis kogenud tervishoiutöötaja.
English: As for every medicine, the company provided studies on the quality of Darunavir Krka d.d.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud Darunavir Krka d.d.
English: It is given with low-dose ritonavir or, in adults, with cobicistat.
Estonian: Seda manustatakse väikeses annuses ritonaviiriga või täiskasvanutel koos kobitsistaadiga.
English: What measures are being taken to ensure the safe and effective use of Darunavir Krka d.d.
Estonian: Mis meetmed võetakse, et tagada Darunavir Krka d.d.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Darunavir Krka d.d.
Estonian: ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: has been shown to have comparable quality and to be bioequivalent to Prezista.
Estonian: võrreldav kvaliteet ja bioekvivalentsus ravimiga Prezista.
English: For practical information about using Darunavir Krka d.d., patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: used?
Estonian: toimib?
English: contains the active substance darunavir.
Estonian: sisaldab toimeainena darunaviiri.
English: on 18 January 2018.
Estonian: EMA/23169/2018
English: This is a summary of the European public assessment report (EPAR) for Darunavir Krka d.d.
Estonian: Euroopa avaliku hindamisaruande täistekst Darunavir Krka d.d.
English: The active substance in Darunavir Krka d.d., darunavir, is a protease inhibitor.
Estonian: toimeaine darunaviir on proteaasiinhibiitor.
English: Other information about Darunavir Krka d.d.
Estonian: Muu teave Darunavir Krka d.d.
English: is available as tablets.
Estonian: Darunavir Krka d.d.-d turustatakse tablettidena.
English: Therefore, the Agency's view was that, as for Prezista, the benefit outweighs the identified risk.
Estonian: Seetõttu on amet arvamusel, et nagu ka Prezista korral, ületab ravimi Darunavir Krka d.d.
English: The Agency recommended that Darunavir Krka d.d.
Estonian: Amet soovitas Darunavir Krka d.d.
English: This means that Darunavir Krka d.d.
Estonian: See tähendab, et Darunavir Krka d.d.
English: What is Darunavir Krka d.d.
Estonian: Mis on Darunavir Krka d.d.
English: Darunavir Krka d.d., taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Koos teiste HIV-ravimitega kasutatav Darunavir Krka d.d.
English: Why is Darunavir Krka d.d.
Estonian: Miks Darunavir Krka d.d.
English: How does Darunavir Krka d.d.
Estonian: Kuidas Darunavir Krka d.d.
English: List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, applicant(s) in the Member States
Estonian: Ravimite nimetuste, ravimvormi, tugevuste, manustamisviisi, taotleja loetelu liikmesriikides
English: Italy
Estonian: I lisa
English: Spain
Estonian: Taotleja
English: Didanosine 400 mg gastroresistant capsules, hard
Estonian: Ravimi väljamõeldud nimetus Tugevus
English: Didanosine 250 mg gastroresistant capsules, hard
Estonian: Ravimvorm Manustamisviis
English: United Kingdom
Estonian: EL/EMP Liikmesriik
English: The recommended dose is 150 mg twice a day.
Estonian: Soovitatav annus on 150 mg kaks korda ööpäevas.
English: Further information on Verzenios can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Verzeniose kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Verzenios?
Estonian: Mis meetmed võetakse, et tagada Verzeniose ohutu ja efektiivne kasutamine?
English: Verzenios is available as tablets (50 mg, 100 mg and 150 mg).
Estonian: Verzeniost turustatakse tablettidena (50 mg, 100 mg ja 150 mg).
English: The European Medicines Agency decided that the benefits of Verzenios are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Verzeniose kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Verzenios (abemaciclib)
Estonian: Verzenios (abematsikliib)
English: Other information about Verzenios
Estonian: Muu teave Verzeniose kohta
English: As for all medicines, data on the use of Verzenios are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Verzeniose kasutamise kohta pidevat järelevalvet.
English: Data were considered sufficient to conclude that Verzenios can be of benefit also in women who have not yet been through the menopause.
Estonian: Andmeid peeti piisavaks järeldamaks, et Verzenios võib olla kasulik ka menopausieelses eas naistel.
English: Verzenios contains the active substance abemaciclib.
Estonian: Verzenios sisaldab toimeainena abematsikliibi.
English: Regarding safety, the main risk is diarrhoea, which is considered manageable with dose reduction.
Estonian: Peamine ohutusrisk on kõhulahtisus, mida peetakse hallatavaks annuse vähendamisega.
English: Side effects reported with Verzenios are carefully evaluated and any necessary action taken to protect patients.
Estonian: Verzeniose kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What is Verzenios and what is it used for?
Estonian: Mis on Verzenios ja milleks seda kasutatakse?
English: If the patient experiences certain side effects, treatment may need to be interrupted or stopped, or the dose reduced.
Estonian: Teatud kõrvalnähtude tekkimisel võib olla vaja ravi katkestada või lõpetada või annust vähendada.
English: It is used together with a hormonal medicine, either an aromatase inhibitor or fulvestrant.
Estonian: Seda kasutatakse koos hormoonravimiga - kas aromataasi inhibiitori või fulvestrandiga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Verzenios have been included in the summary of product characteristics and the package leaflet.
Estonian: Verzeniose ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Verzenios, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Verzeniose kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The most common side effects with Verzenios (which may affect more than 1 in 10 people) are diarrhoea, infections, neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts), tiredness, nausea (feeling sick), vomiting and decreased appetite.
Estonian: Verzeniose kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on kõhulahtisus, infektsioonid, neutropeenia (neutrofiilide ehk teatud leukotsüütide vähesus), aneemia (erütrotsüütide vähesus), väsimus, iiveldus, oksendamine ja söögiisu vähenemine.
English: Grapefruit juice should be avoided during treatment with Verzenios as it may affect the way the medicine is absorbed and broken down in the body.
Estonian: Verzeniosega toimuva ravi ajal peab vältima greibimahla, sest see võib mõjutada ravimi imendumist ja lagunemist organismis.
English: For the full list of side effects and restrictions of Verzenios, see the package leaflet.
Estonian: Verzeniose kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: How does Verzenios work?
Estonian: Kuidas Verzenios toimib?
English: In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably.
Estonian: Mõne vähitüübi, sealhulgas HR-positiivse rinnavähi korral on CDK4 ja CDK6 aktiivsus suurenenud, mis aitab vähirakkudel kontrollimatult vohada.
English: Verzenios can only be used when the cancer cells have certain types of receptor (called hormone receptors) on their surface (HR-positive) and do not produce abnormally large quantities of another receptor called HER2 (HER2-negative).
Estonian: Verzeniost tohib kasutada ainult siis, kui vähirakkude pinnal on teatud tüüpi retseptorid - hormoonretseptorid - (vähirakud on HR-positiivsed) ja kui vähirakkudes ei teki suures koguses teist retseptorit, HER2 (vähirakud on HER2-negatiivsed).
English: Two main studies, involving 1,162 women, mostly postmenopausal, with HR-positive, HER2-negative breast cancer that had started to spread, showed that Verzenios can prolong the time patients live without their disease getting worse (progression-free survival).
Estonian: Kahes põhiuuringus, milles osales 1162 (enamikus menopausijärgses eas) naist, kellel oli HR-positiivne HER2-negatiivne metastaatiline rinnavähk, tõendati, et Verzeniosega on võimalik pikendada patsientide progresseerumiseta elumust (kui kaua patsiendid elavad ilma haiguse süvenemiseta).
English: By blocking CDK4 and CDK6, Verzenios slows the growth of HR-positive breast cancer cells.
Estonian: CDK4 ja CDK6 blokeerimisega aeglustab Verzenios HRpositiivsete rinnavähirakkude kasvu.
English: How is Verzenios used?
Estonian: Kuidas Verzeniost kasutatakse?
English: Verzenios can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Estonian: Ravi peab alustama ja jälgima vähiravimite kasutamises kogenud arst.
English: A third study, conducted in 132 women who had received previous cancer treatment, failed to demonstrate that Verzenios used on its own was of benefit in the treatment of HR-positive, HER2negative breast cancer that had started to spread.
Estonian: Kolmandas uuringus, milles osales 132 varem vähiravi saanud naist, ei suudetud tõendada Verzeniose ainuravimina kasutamise kasulikkust HR-positiivse HER2-negatiivse metastaatilise rinnavähi ravis.
English: The dose should be reduced if the patient is also taking certain medicines called ‘CYP3A4 inhibitors'.
Estonian: Kui patsient võtab lisaks CYP3A4 inhibiitoreid (teatud tüüpi ravimid), tuleb annust vähendada.
English: What are the risks associated with Verzenios?
Estonian: Mis riskid Verzeniosega kaasnevad?
English: In the second study women taking Verzenios and fulvestrant lived on average 16 months without their disease getting worse, compared with 9 months for women taking placebo and fulvestrant.
Estonian: Teises uuringus oli keskmine progresseerumiseta elumus Verzeniost ja fulvestranti kasutanud naistel 16 kuud ning platseebot ja fulvestranti kasutanud naistel 9 kuud.
English: In the first study women taking Verzenios and an aromatase inhibitor (letrozole or anastrozole) lived on average 28 months without their disease getting worse compared with 15 months for women taking placebo (a dummy treatment) and an aromatase inhibitor.
Estonian: Esimeses uuringus oli keskmine progresseerumiseta elumus Verzeniost ja aromataasi inhibiitorit (letrosool või anastrosool) kasutanud naistel 28 kuud ning platseebot (näiv ravim) ja aromataasi inhibiitorit kasutanud naistel 15 kuud.
English: Verzenios used with an aromatase inhibitor or fulvestrant increased the time it took for the disease to get worse in postmenopausal women with HR-positive and HER2-negative breast cancer that is advanced or metastatic.
Estonian: Koos aromataasi inhibiitori või fulvestrandiga kasutatuna pikendas Verzenios kaugelearenenud või metastaatilise HR-positiivse HER2-negatiivse rinnavähiga menopausijärgses eas naistel aega haiguse süvenemiseni.
English: An overview of Verzenios and why it is authorised in the EU
Estonian: Ülevaade ravimist Verzenios ja ELis müügiloa väljastamise põhjendus
English: What benefits of Verzenios have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Verzeniose kasulikkus?
English: Verzenios is a cancer medicine used to treat women with breast cancer that is advanced or has spread to other parts of the body.
Estonian: Verzenios on vähiravim, mida kasutatakse kaugelearenenud või metastaatilise (organismis mujale levinud) rinnavähiga naiste raviks.
English: The active substance in Verzenios, abemaciclib, blocks the activity of enzymes known as cyclindependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide.
Estonian: Verzeniose toimeaine abematsikliib blokeerib tsükliinsõltuvate kinaaside CDK 4 ja CDK 6 toime.
English: Ref.: EMEA/350155/2009 EMEA/H/C/1015
Estonian: Viide: EMEA/350155/2009 EMEA/H/C/1015
English: The vaccine is given according to official recommendations.
Estonian: Vaktsiini manustatakse ametlike soovituste kohaselt.
English: This may help to protect against the disease caused by the virus.
Estonian: See võib aidata kaitsta haiguse eest, mida viirus põhjustab.
English: These patients needed double doses of the vaccine for protection.
Estonian: Need patsiendid vajasid kaitse tekkimiseks vaktsiini kahekordset annust.
English: The virus has first been inactivated so that it does not cause any disease.
Estonian: Kõigepealt viirus inaktiveeritakse, et see ei põhjustaks haigust.
English: The Committee recommended that the vaccine be given marketing authorisation.
Estonian: Komitee soovitas anda vaktsiinile müügiloa.
English: This authorisation was based on the authorisation granted to Prepandrix in 2008 (‘informed consent').
Estonian: Müügiluba põhineb 2008. aastal antud Prepandrixi müügiloal (teabel põhineva nõusoleku alusel).
English: Other information about the vaccine:
Estonian: Muu teave vaktsiini kohta
English: The vaccine can only be obtained with a prescription.
Estonian: Seda vaktsiini saab üksnes retsepti alusel.
English: Vaccination should be delayed in people who have a sudden fever.
Estonian: Vaktsineerimine tuleb edasi lükata patsientidel, kellel tekib äkki palavik.
English: A further study looked at the immunogenicity of single or double doses of the vaccine in 437 people aged over 60 years.
Estonian: Veel ühes uuringus jälgiti vaktsiini ühe- või kahekordse annuse immunogeensust 437 üle 60-aastasel patsiendil.
English: In elderly people, single doses of this vaccine also met these criteria, except for in the small number of patients aged over 80 years who did not have any protection against the virus at the start of the study.
Estonian: Eakatel vastasid vaktsiini ühekordsed annused kriteeriumile peaaegu, välja arvatud vähestel üle 80aastastel patsientidel, kellel ei olnud viiruse vastu uuringu alguses mingit kaitset.
English: The main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times: before vaccination, on the day of the second injection (day 21) and 21 days later (day
Estonian: Efektiivsuse põhinäitaja oli gripiviiruse vastu tekkinud antikehade sisaldus veres kolmel eri ajal: enne vaktsineerimist, teise süste päeval (21. päev) ja 21 päeva hiljem (42. päev).
English: The injections were given 21 days apart.
Estonian: Süstete vahele jäi 21 päeva.
English: The main study of the vaccine included 400 healthy adults aged between 18 and 60 years and compared the ability of different doses of the vaccine, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity').
Estonian: Vaktsiini põhiuuringus osales 400 tervet täiskasvanut vanuses 18-60 aastat ning selles võrreldi vaktsiini (koos adjuvandiga või ilma) eri annuste suutlikkust põhjustada antikehade teket (immunogeensust).
English: According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a prepandemic vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
Estonian: Inimravimite komitee kriteeriumide kohaselt võib prepandeemilist vaktsiini pidada sobivaks, kui see tekitab antikehade kaitsva sisalduse vähemalt 70%-l inimestest.
English: The main study showed that the vaccine containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria.
Estonian: Põhiuuring näitas, et 3,75 mikrogrammi hemaglutiniini ja adjuvanti sisaldav vaktsiin põhjustas sellele kriteeriumile vastava antikehade tekke.
English: The vaccine contains a flu strain called ‘A/VietNam/1194/2004 NIBRG-14' (H5N1).
Estonian: Vaktsiin sisaldab gripiviiruse tüve A/VietNam/1194/2004 NIBRG-14 (H5N1).